

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MEDER *et al.*

Appl. No.: (to be assigned; U.S. National
Phase of PCT/EP2003/011799)

Int'l Filing Date: October 24, 2003

For: **Human Chondroosteomodulin (TIG2),
Production, and Use for the Treatment
or Diagnosis of Bone Diseases,
Cartilage Diseases, Obesity,
Inflammatory Diseases, and Skin
Diseases**

Confirmation No.: (to be assigned)

Art Unit: (to be assigned)

Examiner: (to be assigned)

Atty. Docket: 2388.0010000/SRL/BLS

**Authorization to Treat a Reply as Incorporating an
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**


Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Bryan L. Skelton
Agent for Applicants
Registration No. 50,893

Date: April 29, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
393161_1.DOC